[HTML][HTML] Clinical outcomes of lung adenocarcinoma patients harboring uncommon epidermal growth factor receptor (EGFR) mutations treated with EGFR-tyrosine …
J Si, X Gu, W Wang, S Ying… - Annals of Palliative …, 2022 - apm.amegroups.org
Background: This study aimed to explore the efficacy of different epidermal growth factor
receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung adenocarcinoma (AC) patients …
receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung adenocarcinoma (AC) patients …
Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with …
H Li, C Wang, Z Wang, Y Hu, G Zhang, M Zhang… - Lung Cancer, 2019 - Elsevier
Purpose This study aims to understand the effects and long-term survival of 1st generation
epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) or platinum-based …
epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) or platinum-based …
Survival‑associated factors of first‑line EGFR‑tyrosine kinase inhibitor responders and non‑responders in lung adenocarcinoma patients with common EGFR …
MS Hung, YH Fang, YC Lin… - Molecular and …, 2018 - spandidos-publications.com
The aim of the present retrospective cohort study was to elucidate the clinical presentation of
epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitor (TKI) responders and non …
epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitor (TKI) responders and non …
Better progression-free survival in elderly patients with stage IV lung adenocarcinoma harboring uncommon epidermal growth factor receptor mutations treated with …
MJ Tsai, JY Hung, MH Lee, CY Kuo, YC Tsai, YM Tsai… - Cancers, 2018 - mdpi.com
Patients with lung adenocarcinoma harboring common epidermal growth factor receptor
(EGFR) mutations usually have a good response rate (RR) and longer progression-free …
(EGFR) mutations usually have a good response rate (RR) and longer progression-free …
EGFR–TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation
DH Koo, K Kim, CM Choi, DH Lee, JC Lee… - Cancer chemotherapy …, 2015 - Springer
Purpose Although epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR–TKIs)
have become key therapeutic agents for non-small cell lung cancer (NSCLC) patients with …
have become key therapeutic agents for non-small cell lung cancer (NSCLC) patients with …
Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations
L Peng, ZG Song, SC Jiao - Scientific reports, 2014 - nature.com
The efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) in
patients with non-small cell lung cancer (NSCLC) is related to EGFR mutations. Although the …
patients with non-small cell lung cancer (NSCLC) is related to EGFR mutations. Although the …
Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis
H Liu, G Han, M Peng, Y Weng, J Yuan, G Yang… - Current Medical …, 2017 - Springer
With the development of molecular pathology, many types of epidermal growth factor
receptor (EGFR) mutations have been identified. The efficacy of EGFR tyrosine kinase …
receptor (EGFR) mutations have been identified. The efficacy of EGFR tyrosine kinase …
First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution's clinical practice experience
X Yu, X Zhang, Z Zhang, Y Lin, Y Wen, Y Chen… - Cancer …, 2018 - Springer
Background The antitumour efficacy of tyrosine kinase inhibitors (TKIs) in lung cancer
patients with compound epidermal growth factor receptor (EGFR) mutations has not been …
patients with compound epidermal growth factor receptor (EGFR) mutations has not been …
Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients
K Chen, X Yu, H Wang, Z Huang, Y Xu, L Gong… - Cancer Chemotherapy …, 2017 - Springer
Purpose Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is the
standard therapy for advanced lung adenocarcinomas with common EGFR mutations …
standard therapy for advanced lung adenocarcinomas with common EGFR mutations …
Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma …
Background Mutations in the epidermal growth factor receptor (EGFR) have been
associated with a marked therapeutic response to EGFR-tyrosine kinase inhibitors (TKIs) in …
associated with a marked therapeutic response to EGFR-tyrosine kinase inhibitors (TKIs) in …
相关搜索
- kinase inhibitor egfr mutations
- growth factor receptor mutations
- growth factor lung adenocarcinoma
- egfr tyrosine clinical outcomes
- lung adenocarcinoma patients
- common egfr mutations
- pulmonary adenocarcinoma with egfr mutation
- efficacy analysis egfr mutations
- associated factors egfr mutations
- complex egfr mutations
- treatment timing egfr mutation
- long term egfr mutations
- retrospective analysis egfr mutations
- growth factor elderly patients
- progression patterns lung adenocarcinoma
- growth factor progression patterns